Genmab EPS Falls Short by $0.11, Revenue Hits $1.06B and Short Interest Drops
Genmab reported earnings per share of $0.35 versus the $0.46 estimate while generating $1.06 billion in revenue. Short interest declined 15.1% to 8.4 million shares and AllianceBernstein raised its stake by 2.7% to 11 million shares.
1. Quarterly Financial Results
Genmab posted earnings per share of $0.35 compared to the $0.46 consensus and delivered revenue of $1.06 billion, slightly above the $1.055 billion estimate.
2. Decline in Short Interest
Short interest in GMAB shares fell 15.1% to approximately 8.4 million shares by January 30th, indicating reduced bearish positioning.
3. Institutional Stake Increase
AllianceBernstein boosted its holding in Genmab by 2.7%, now owning around 11 million shares valued at roughly $336 million, reflecting growing institutional confidence.
4. Robust Valuation Metrics
Genmab trades at a P/E ratio of 17.76 and a P/S ratio of 8.31, with an EV/S of 8.20, EV/OCF of 35.91, debt-to-equity of 0.025 and a current ratio of 6.03.